Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes
Autor: | Masahiro Inagaki, Yuya Nakamura, Yoshikazu Goto, Tatsunori Oguchi, Tetsuhito Nohara, Akihiko Yura, Yuji Kiuchi, Hiromichi Gotoh, Isao Ohsawa, Shinichi Iwai, Sachiyo Kenmotsu, Naoki Sato, Mayumi Tsuji, Shiho Yamadera |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Lipopolysaccharide Immunology Inflammation Anti-inflammatory effects Linagliptin Interleukin 6 030204 cardiovascular system & hematology Pharmacology Human U937 monocytes 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine lcsh:Pathology medicine Immunology and Allergy biology U937 cell business.industry Interleukin 030104 developmental biology chemistry biology.protein Tumor necrosis factor alpha medicine.symptom business Fetal bovine serum lcsh:RB1-214 medicine.drug Research Article |
Zdroj: | Inflammation and Regeneration Inflammation and Regeneration, Vol 38, Iss 1, Pp 1-7 (2018) |
ISSN: | 1880-9693 |
Popis: | Background Atherosclerosis and inflammation are more common in patients with diabetes than in patients without diabetes, and atherosclerosis progression contributes to inflammation. Therefore, anti-inflammatory therapy is important for the prognosis of patients with diabetes. Linagliptin is the only bile-excreted, anti-diabetic oral dipeptidyl peptidase-4 (DPP-4) inhibitor. Although the anti-inflammatory effects of DPP-4 inhibitors in vivo and in vitro have been reported, few in vitro studies have examined the effects of linagliptin using monocytes, which play a central role in arteriosclerosis-related inflammation. Herein, we assessed the anti-inflammatory effects of linagliptin in human U937 monocytes. Methods U937 cells at densities of 1 × 106 cells/mL were cultured in Roswell Park Memorial Institute medium supplied with 10% fetal bovine serum and treated with 100 nM phorbol myristate acetate for 48 h for differentiation into macrophages. The media were replaced, and the cells were pretreated with 1, 5, 10, 50, and 100 nM linagliptin for 1 h or were left untreated. The media were then replaced again, and the cells were treated with 1 μg/mL lipopolysaccharide (LPS) or 10 nM interleukin (IL)-1β only, in combination with 1, 5, 10, 50, and 100 nM linagliptin or were left untreated. The extracted media were used to measure IL-6 and tumor necrosis factor (TNF)-α levels using enzyme-linked immunosorbent assay kits. Results LPS alone significantly increased IL-6 and TNF-α production compared with the control treatment. The treatment of cells with linagliptin at all concentrations significantly inhibited the LPS-stimulated IL-6 and TNF-α production. Meanwhile, IL-1β alone significantly increased IL-6 production compared with the control treatment. No significant difference in IL-6 production was noted between the cells treated with IL-1β and simultaneous treatment with IL-1β and linagliptin. Conclusions Linagliptin inhibited LPS-induced inflammation in human monocytic U937 cells. |
Databáze: | OpenAIRE |
Externí odkaz: |